Related Experiment Video
Updated: Aug 8, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
Inhibition by transmembrane peptides of chimeric insulin receptors
A Bennasroune1, A Gardin, C Auzan
1INSERM Unit 575, Université Louis Pasteur, 5 rue Blaise Pascal, 67084, Strasbourg, France.
Abstract:
Receptor tyrosine kinases play essential roles in cell proliferation and differentiation. We have recently shown that peptides corresponding to the transmembrane domains of the epidermal growth factor (EGF) and ErbB2 receptors inhibit their corresponding receptor activation in cancer cell lines. We extend this observation to cells transfected with chimeric insulin receptors where the transmembrane domain has been replaced by that of the EGF receptor or a mutated Erb2 domain. Peptides corresponding to the transmembrane domains of the EGF receptor and ErbB2 are able to inhibit specifically the autophosphorylation of insulin receptors with the corresponding domain. This inhibitory effect is correlated with the propensity of the different transmembrane domains to self-associate in a genetic reporter assay. Thus, our data strengthen the notion that transmembrane domains are involved in erbB receptor activation, and that these receptors can be modulated by inhibiting protein-protein interactions within the membrane.
Insights
Transmembrane domains of epidermal growth factor (EGF) and ErbB2 receptors can inhibit receptor activation. This suggests targeting protein interactions within cell membranes offers a new therapeutic strategy for cancer.
Area of Science:
- Molecular biology
- Cell signaling
- Biochemistry
Background:
- Receptor tyrosine kinases are crucial for cell growth and development.
- Previous studies indicated transmembrane domains of EGF and ErbB2 receptors inhibit their activation in cancer cells.
Purpose of the Study:
- To investigate if transmembrane domains of EGF and ErbB2 receptors can inhibit chimeric insulin receptors.
- To explore the role of transmembrane domains in erbB receptor activation and modulation.
Main Methods:
- Transfection of cells with chimeric insulin receptors.
- Utilizing peptides corresponding to transmembrane domains of EGF and ErbB2 receptors.
- Employing a genetic reporter assay to assess protein self-association.
Main Results:
- EGF and ErbB2 receptor transmembrane domain peptides inhibited autophosphorylation of chimeric insulin receptors.
- Inhibitory effects correlated with the propensity of transmembrane domains to self-associate.
- Demonstrated specificity in the inhibition of receptor activation.
Conclusions:
- Transmembrane domains are integral to erbB receptor activation.
- Inhibiting protein-protein interactions within the cell membrane can modulate receptor activity.
- This research provides a basis for developing novel therapeutic strategies targeting receptor tyrosine kinases.
Related Concept Videos
Insulin Secretory Vesicles
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Insulin: The Receptor and Signaling Pathways
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors

